Literature DB >> 23896689

The identification of naturally occurring neoruscogenin as a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1).

Stéphane Helleboid1, Christian Haug, Kai Lamottke, Yijun Zhou, Jianbing Wei, Sébastien Daix, Linda Cambula, Géraldine Rigou, Dean W Hum, Robert Walczak.   

Abstract

Plants represent a tremendous structural diversity of natural compounds that bind to many different human disease targets and are potentially useful as starting points for medicinal chemistry programs. This resource is, however, still underexploited due to technical difficulties with the identification of minute quantities of active ingredients in complex mixtures of structurally diverse compounds upon raw phytomass extraction. In this work, we describe the successful identification of a novel class of potent RAR-related orphan receptor alpha (RORα or nuclear receptor NR1F1) agonists from a library of 12,000 plant extract fractions by using an optimized, robust high-throughput cell-free screening method, as well as an innovative hit compound identification procedure through further extract deconvolution and subsequent structural elucidation of the active natural compound(s). In particular, we demonstrate that neoruscogenin, a member of the steroidal sapogenin family, is a potent and high-affinity RORα agonist, as shown by its activity in RORα reporter assays and from its effect on RORα target gene expression in vitro and in vivo. Neoruscogenin represents a universal pharmacological tool for RORα research due to its specific selectivity profile versus other nuclear receptors, its excellent microsomal stability, good bioavailability, and significant peripheral exposure in mouse.

Entities:  

Keywords:  NR1F1; RORα; high-throughput screening; natural products; neoruscogenin; plant extracts

Mesh:

Substances:

Year:  2013        PMID: 23896689     DOI: 10.1177/1087057113497095

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  8 in total

Review 1.  Circadian rhythm as a therapeutic target.

Authors:  Wei Ruan; Xiaoyi Yuan; Holger K Eltzschig
Journal:  Nat Rev Drug Discov       Date:  2021-02-15       Impact factor: 84.694

Review 2.  REV-ERB and ROR nuclear receptors as drug targets.

Authors:  Douglas J Kojetin; Thomas P Burris
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

Review 3.  Development and Therapeutic Potential of Small-Molecule Modulators of Circadian Systems.

Authors:  Zheng Chen; Seung-Hee Yoo; Joseph S Takahashi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-10-02       Impact factor: 13.820

4.  Coronavirus disease 2019 drug discovery through molecular docking.

Authors:  Sweta Singh; Hector Florez
Journal:  F1000Res       Date:  2020-06-03

5.  Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 Mpro for pharmacological interventions in COVID-19 pandemic.

Authors:  Armiya Sultan; Rafat Ali; Tahira Sultan; Sher Ali; Nida Jamil Khan; Arti Parganiha
Journal:  Chronobiol Int       Date:  2021-04-06       Impact factor: 2.877

Review 6.  Unraveling the physiological roles of retinoic acid receptor-related orphan receptor α.

Authors:  Ji Min Lee; Hyunkyung Kim; Sung Hee Baek
Journal:  Exp Mol Med       Date:  2021-09-29       Impact factor: 12.153

7.  Development of Non-Ethoxypropanoic Acid Type Cryptochrome Inhibitors with Circadian Molecular Clock-Enhancing Activity by Bioisosteric Replacement.

Authors:  Yong Uk Jeong; Hyo-Eon Jin; Hye Young Lim; Goyeong Choi; Hansol Joo; Bohun Kang; Ga-Hyun Lee; Kwang-Hyeon Liu; Han-Joo Maeng; Sooyoung Chung; Gi Hoon Son; Jong-Wha Jung
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-24

8.  Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins.

Authors:  Stephanie Rebensburg; Markus Helfer; Martha Schneider; Herwig Koppensteiner; Josef Eberle; Michael Schindler; Lutz Gürtler; Ruth Brack-Werner
Journal:  Sci Rep       Date:  2016-02-02       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.